Table 2—

Characteristics of patients

TAControlsp-value
Patients n118102
Age yrs61.2±17.661.1±17.4ns
Sex
 Males75 (64)74 (72)
 Females43 (36)28 (28)ns
Diagnosis
 COPD57 (48)44 (43)ns
 Restrictive14 (12)14 (14)
 NM24 (20)26 (25.5)
 ALS12 (10.2)10 (9.8)
 Other11(9.3)8 (7.9)
Ex-smokers55 (47)43 (42)ns
Current smokers7 (6)9 (9)
Symptoms yrs9.5±9.310.3±8.9ns
Patients under NMV50 (42)52 (51)ns
Patients under IMV26 (22)21 (21)ns
Patients under SB without MV42 (36)29 (28)ns
HMV yrs2.1±1.81.9±2.0ns
Patients on LTOT75 (64)63 (62)ns
LTOT yrs4.1±3.14±3.2ns
FEV1# % pred39±2334±16ns
VC % pred49±2644±18ns
Pa,O2+ mmHg65±1463±14ns
Pa,CO2+ mmHg46±847±9ns
pH+7.40±0.387.40±0.40ns
MIP§ % pred42±3038±15ns
MEPƒ % pred39±2441±19ns
Comorbidities1.69±1.41.57±1.24ns
PLS2.50±0.942.45±0.86ns
  • Data are presented as n (%) or mean±sd, unless otherwise stated. TA: tele-assistance; COPD: chronic obstructive pulmonary disease; NM: neuromuscular diseases; ALS: amyotrophic lateral sclerosis; NMV: noninvasive mechanical ventilation; IMV: invasive mechanical ventilation; SB: spontaneous breathing; MV: mechanical ventilation; HMV: home mechanical ventilation; LTOT: long-term oxygen therapy; FEV1: forced expiratory volume in one second; % pred: % predicted; VC: vital capacity; Pa,O2: arterial oxygen tension; Pa,CO2: carbon dioxide arterial tension; MIP: maximal inspiratory pressure; MEP: maximal expiratory pressure; PLS pre-morbidity life score 24; ns: nonsignificant. #: available for 92 patients in TA group and 73 in controls; : available for 79 patients in TA group and 70 in controls; +: measured in room air and available for 85 patients in TA group and 78 in controls; §: available for 61 patients in TA group and in 59 controls; ƒ: available for 59 patients in TA group and in 57 controls.